KMTS
Kestra Medical·NASDAQ
--
--(--)
--
--(--)
4.84 / 10
Netural
Fund flow data reveal a generally positive trend, with inflows dominant in block, medium, large, and extra-large categories (overall inflow ratio 0.516). However, small-cap flows are negative, indicating fragmented demand. Analyst coverage is limited to three reports, with two Buys and one Neutral; historical win rates for these analysts are modest (33-50%), and the market-weighted rating (1.81) lags the current price rise, suggesting limited conviction.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
67%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-15
InstitutionGoldman Sachs
Times predicted3
Historical Win Rate33.3%
What is the analyst consensus for KMTS?
- KMTS holds a Bearish analyst rating, with 67% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 4.84/10 (Netural).
